← DPP-4 inhibitors × glycemic control

TrialEndocrine research2017

Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.

Mojca Jensterle et al.PubMed ↗Publisher ↗

  • ALO 25 mg QD added to MET 1000 mg BIDlooks good hereLower insulin resistance, no range given.No ranges given.
  • ALO 25 mg QD and PIO 30 mg QD added to MET 1000 mg BIDlooks good hereLower insulin resistance, no range given.No ranges given.
  • ALO 25 mg QD added to MET 1000 mg BID (for MET-ALO) or ALO 25 mg QD and PIO 30 mg QD added to MET 1000 mg BID (for MET-ALO-PIO)no clear effectHigher insulin sensitivity after meal ingestion, no range given.No ranges given.

What the trial testedas reported · 30 people · 2017

No range given

Reported lower insulin resistance, no range given

−1.60

ALO 25 mg QD added to MET 1000 mg BID vs MET 1000 mg BID alone (implied baseline or control)

As reported

difference −1.60, no interval · the paper's word: HOMA-IR

No range given

Reported lower insulin resistance, no range given

−2.90

ALO 25 mg QD and PIO 30 mg QD added to MET 1000 mg BID vs MET 1000 mg BID alone (implied baseline or control)

As reported

difference −2.90, no interval · the paper's word: HOMA-IR

+1 more in the walkthrough ↓

Who was studied, and how

30people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

ALO 25 mg QD added to MET 1000 mg BID
MET 1000 mg BID alone (implied baseline or control)

Reported lower insulin resistance, no range given−1.60

randomised

The trial randomly assignedassigned by chance

ALO 25 mg QD and PIO 30 mg QD added to MET 1000 mg BID
MET 1000 mg BID alone (implied baseline or control)

Reported lower insulin resistance, no range given−2.90

randomised

the abstract, start to end

… in a significant decrease of HOMA-IR (by 1.6±2.3 (p=0.039) and 2.9±3.3 (p=0.001), respectively) and an increase in insulin sensitivity (IS) after meal ingestion (oral glucose IS) by 31.4±97.5 ml.min CONCLUSIONS: ALO …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
HOMA-IRALO 25 mg QD added to MET 1000 mg BID vs MET 1000 mg BID alone (implied baseline or control)
−1.60
HOMA-IRALO 25 mg QD and PIO 30 mg QD added to MET 1000 mg BID vs MET 1000 mg BID alone (implied baseline or control)
−2.90
Insulin sensitivity (IS) after meal ingestion (oral glucose IS)ALO 25 mg QD added to MET 1000 mg BID (for MET-ALO) or ALO 25 mg QD and PIO 30 mg QD added to MET 1000 mg BID (for MET-ALO-PIO) vs MET 1000 mg BID alone (implied baseline or control)
31.4
MetforminDPP-4 inhibitorsThiazolidinedionesGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it

Metformin × glycemic controlhelps?replicated

unlikelylikely
0.840.84 without it

Thiazolidinediones × glycemic controlhelps?settled

unlikelylikely
0.830.80 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 7

9 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 28323503